EICHOR

Recruiting studies: Aggressive B Cell Lymphomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Phase 2 · 13 location(s) · The Lymphoma Academic Research Organisation · NCT06271057 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT06536049 Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373 The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT06911710 Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06996132 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535 A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 · 34 location(s) · Universität Münster · NCT07197307 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648 Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06550427 Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Phase 3 · 17 location(s) · Universität des Saarlandes · NCT05820841 Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT07168980 GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363 Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
NA · 1 location(s) · University Health Network, Toronto · NCT06485076 SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518 Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · 86 location(s) · National Cancer Institute (NCI) · NCT06649812 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Phase 2 · 36 location(s) · Ryvu Therapeutics SA · NCT06534437 A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033 A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-
Phase 1 · 20 location(s) · Regeneron Pharmaceuticals · NCT05685173 Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Phase 2 · 1 location(s) · Koo Foundation Sun Yat-Sen Cancer Center · NCT06461182 The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527 An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressi
EARLY_Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07344818 Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631 Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive La
Phase 1 · 1 location(s) · University of Washington · NCT04231877 Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07059741

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →